ABCL AbCellera Biologics Inc

Price (delayed)

$3.625

Market cap

$1.06B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$974.24M

AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners ...

Highlights

AbCellera Biologics's debt has decreased by 7% YoY and by 5% from the previous quarter

AbCellera Biologics's net income has plunged by 192% YoY and by 13% from the previous quarter

ABCL's EPS has plunged by 191% YoY and by 13% from the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.abcellera.com

Peers: OMER OMGA

Key stats

What are the main financial stats of ABCL

Market

Shares outstanding

292.78M

Market cap

$1.06B

Enterprise value

$974.24M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

0.91

Price to sales (P/S)

27.57

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

25.62

Earnings

Revenue

$38.03M

EBIT

-$174.03M

EBITDA

-$143.14M

Free cash flow

-$120.82M

Per share

EPS

-$0.51

Free cash flow per share

-$0.42

Book value per share

$3.97

Revenue per share

$0.13

TBVPS

$4.56

Balance sheet

Total assets

$1.49B

Total liabilities

$335.78M

Debt

$71.22M

Equity

$1.15B

Working capital

$752.97M

Liquidity

Debt to equity

0.06

Current ratio

7.33

Quick ratio

6.86

Net debt/EBITDA

0.61

Margins

EBITDA margin

-376.4%

Gross margin

100%

Net margin

-385%

Operating margin

-623.8%

Efficiency

Return on assets

-9.7%

Return on equity

-12.4%

Return on invested capital

-15.7%

Return on capital employed

-12.7%

Return on sales

-457.7%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

ABCL stock price

How has the AbCellera Biologics stock price performed over time

Intraday

-7.05%

1 week

-7.29%

1 month

-20.85%

1 year

-46.14%

YTD

-36.51%

QTD

-19.98%

Financial performance

How have AbCellera Biologics's revenue and profit performed over time

Revenue

$38.03M

Gross profit

$38.03M

Operating income

-$237.21M

Net income

-$146.4M

Gross margin

100%

Net margin

-385%

AbCellera Biologics's net income has plunged by 192% YoY and by 13% from the previous quarter

The gross profit has plunged by 92% YoY and by 25% from the previous quarter

The company's revenue has shrunk by 92% YoY and by 25% QoQ

AbCellera Biologics's operating margin has shrunk by 50% QoQ

Growth

What is AbCellera Biologics's growth rate over time

Valuation

What is AbCellera Biologics stock price valuation

P/E

N/A

P/B

0.91

P/S

27.57

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

25.62

ABCL's EPS has plunged by 191% YoY and by 13% from the previous quarter

ABCL's P/B is 35% below its last 4 quarters average of 1.5

The equity has declined by 7% year-on-year and by 2.6% since the previous quarter

The company's revenue has shrunk by 92% YoY and by 25% QoQ

The P/S is 25% more than the last 4 quarters average of 23.7

Efficiency

How efficient is AbCellera Biologics business performance

The ROA has plunged by 196% YoY and by 14% from the previous quarter

AbCellera Biologics's ROE has plunged by 196% YoY and by 16% from the previous quarter

The company's return on invested capital has shrunk by 147% YoY and by 5% QoQ

ABCL's ROS is down by 47% from the previous quarter

Dividends

What is ABCL's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for ABCL.

Financial health

How did AbCellera Biologics financials performed over time

The company's quick ratio fell by 15% YoY and by 11% QoQ

ABCL's current ratio is down by 15% YoY and by 12% QoQ

AbCellera Biologics's debt is 94% less than its equity

The equity has declined by 7% year-on-year and by 2.6% since the previous quarter

AbCellera Biologics's debt has decreased by 7% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.